Blog

Nekson Advisors will be attending, speaking and chairing panels at leading healthtech and medtech events in the UK, Europe, North America and the Middle East throughout 2026.Q1 2026Digital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp; &nbsp; &nbsp;Q2 2026 &nbsp; NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp; &nbsp; HLTH Europe &gt; June 2026, Amsterdam, NetherlandsQ3 2026 &nbsp; HIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp; &nbsp; &nbsp;Q4 2026 &nbsp; World Health Summit 2026 &gt; October 2026, Berlin, Germany &nbsp; HealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp; HLTH USA 2026 &gt; October 2026, USA &nbsp; Barclays Health Elevate &gt; October 2026, London, UK&nbsp; &nbsp; Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp; &nbsp; &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, Germany &nbsp; &nbsp;Venture Capital World Summit &gt; December 2026 Toronto, CanadaOnline Meeting with Nelson AdvisorsPlease schedule an onlne meeting with the team using the link below:﻿<a href="https://scheduler.zoom.us/nelson-advisors/meeting">https://scheduler.zoom.us/nelson-advisors/meeting</a>

Nelson Advisors Conferences and Events 2026

Nelson Advisors advised the Clinic Letter AI founders &nbsp;on their sale to Mayden, backed by G Square Capital.CLAI is the ambient scribe built for the NHS. Ambient Voice Technology (AVT) solutions are being widely adopted by healthcare services due to their ability to significantly reduce manual data entry and give clinicians back valuable time that can be better spent on patient care. CLAI is a simple way to transcribe letters, generate clinical coding and automate follow up orders demonstrating up to 30% reduction in administration.The addition of CLAI strengthens Mayden’s mission to transform health and care by expanding their digital offering, helping to free up capacity for clinicians whilst enabling better outcomes for the people they support.Reece Donovan, CEO at Mayden says: “Welcoming CLAI to Mayden reflects our commitment to developing and supporting tools that make a meaningful difference to those delivering and accessing health and care services. CLAI will join our existing product portfolio – iaptus, theseus and bacpac – and deepens our ability to support services across the NHS, local authorities, VCSE’s and the private sector.At Mayden, our focus is supporting our customers with technology that improves the efficiency and quality of services, the working lives of professionals and the experience of care for the people they serve. That made the addition of CLAI a very simple decision. From the outset, it was clear we share the same values and a commitment to building technology collaboratively with our customers that drive real, tangible value. I’m excited about what we can achieve together.”James Balmain, Co-Founder at CLAI says: “Joining Mayden feels like a natural next step for us. As a small business, CLAI needed the help and support of a larger organisation and in Mayden we’re really confident we’ve found a brilliant owner. There is obvious value for us to add within the community mental health space, as providers begin to unlock the transformative power in AVT technologies – we can’t think of a more suitable use case than longer format mental health encounters.Mayden has a clear and well recognised commitment to building technology that genuinely supports the people using it – this focus on real-world impact is directly aligned with our sense of mission at CLAI. We’re delighted to be a part of the Mayden team and to continue on this journey together”.Source: <a href="https://www.mayden.com/blog/press-releases/clinicletter-ambient-scribe-joins-mayden/" data-mce-href="https://www.mayden.com/blog/press-releases/clinicletter-ambient-scribe-joins-mayden/">https://www.mayden.com/blog/press-releases/clinicletter-ambient-scribe-joins-mayden/</a>

Nelson Advisors advised the Clinic Letter AI founders  on their sale to Mayden, backed by G Square Capital

Nelson Advisors served as exclusive advisors to Wellola on their sale to &nbsp;Mayden, backed by G Square Capital.Wellola was founded in 2016 by clinical entrepreneurs Sonia Neary and Dr Greg Martin, with the simple mission to build a patient engagement platform that empowers healthcare teams to deliver seamless, secure, and personalised digital care.Portasana® is a fully integrated patient engagement platform that supports NHS and international healthcare providers in improving access, enabling safe self-management, and reducing pressure on clinical teams. The platform connects with EPRs including Rio and EMIS, the NHS App, and wider clinical systems, offering a configurable suite of modules such as appointments, letters, messaging, forms, symptom tracking, remote monitoring, surveys and condition-specific journeys to support proactive, remote care.&nbsp;The addition of Wellola strengthens Mayden’s mission to transform health and care by expanding its digital offering and combining two organisations with shared values. Together, Mayden and Wellola are committed to empowering clinicians, improving patient outcomes, and making healthcare systems more efficient and sustainable.Reece Donovan, CEO, Mayden says: “I’m delighted to welcome the Wellola team to Mayden. Portasana adds a powerful, integrated patient engagement platform to our growing portfolio, giving our customers the tools they need to improve access, streamline care, and empower patients to manage their own health safely.Mayden and Wellola hold a shared belief that technology should not only support services to be more efficient, but also make care more meaningful for the people who rely on it. Together, we can reach further and make a bigger impact for both services and the people they serve”Sonia Neary, co-founder of Wellola, says: “Joining Mayden is an exciting step for our team. We’ve always believed that giving people the right tools to understand and manage their own health leads to better outcomes, less pressure on clinicians, and more sustainable services.Being part of Mayden allows us to scale this vision more effectively and support more health and care providers and patients.”Source: <a href="https://www.mayden.com/blog/press-releases/mayden-expands-its-digital-health-portfolio-with-portasana/">https://www.mayden.com/blog/press-releases/mayden-expands-its-digital-health-portfolio-with-portasana/</a>

Nelson Advisors served as exclusive advisors to Wellola on their sale to  Mayden, backed by G Square Capital

FemTech startup Daye has been announced as the winner of the Digital Health Rewired Pitchfest 2026 competition following the live final held at Rewired 2026 at the NEC, Birmingham.What Daye does Daye is a women’s health biotech focused on closing the gender health gap through science-led innovation. Its flagship product is the Daye Diagnostic Tampon, which turns a familiar menstrual product into an at-home tool for detecting high‑risk HPV, the leading cause of cervical cancer. About the Pitchfest 2026 win Pitchfest is Digital Health Rewired’s startup competition, offering finalists exposure to NHS digital leaders, investors, and potential NHS pilot partners. For 2026, 16 startups were shortlisted, eight progressed to the live final, and Daye was selected as overall winner after pitching against other digital health innovators such as Astron Health and Cogniss. The winner receives advisory support and the opportunity for a potential NHS pilot with CW+ and Chelsea and Westminster Hospital, giving Daye a route to scale adoption in the NHS. Why judges backed Daye Judges and organisers highlighted Daye’s strong potential to make a real impact in healthcare by reducing barriers to cervical cancer screening through at-home HPV testing. Daye’s founder, Valentina Milanova, framed the solution as a way to turn the UK’s strong science base into delivery at scale, with the aim of contributing to the eradication of cervical cancer and delivering returns both in lives saved and health system savings.Judging PanelJon Hoeksma, chief executive of Future Health Intelligence Mindy Simon, co-director of NHS Innovation Accelerator Michael Morgan-Curran, chief executive of Asclepius MedTech Limited Lloyd Price, partner at Nelson Advisors Sara Nelson, programme director at DigitalHealth.London Pei-Fen Lin, clinical director of innovation at Moorfields Eye Hospital Chris Sawyer, innovation lead – digital health at Innovate UK The other finalists who competed in the Pitchfest 2026 live final were:Astron Health Cogniss Into-Action.Health, Jigsaw Medical LightHearted AI Mavis Technologies Upskill.HealthSource: <a href="https://www.digitalhealth.net/2026/03/daye-announced-as-rewired-pitchfest-2026-winner/">https://www.digitalhealth.net/2026/03/daye-announced-as-rewired-pitchfest-2026-winner/</a> &nbsp; &nbsp; &nbsp; &nbsp;

FemTech startup Daye wins Digital Health Rewired Pitchfest 2026

US telehealth giant Hims &amp; Hers’ USD 1.15bn acquisition in February of Australian digital health company Eucalyptus is expected to significantly shake up the international digital health sector. The deal, set to close in mid 2026, has certainly caused a stir in Australia, where it is by far the largest acquisition of a preventative healthcare company.Pinning down precise transaction multiples is difficult given the deal’s limited valuation disclosure. But the “up to USD 1.15bn” consideration, which was based on a run‑rate derived from January 2026 revenue, and triple‑digit, year-over-year, quarterly ARR growth through 2025, implies a mid‑ to high‑single‑digit historic revenue multiple and a sizeable payday for Eucalyptus’ founder Tim Doyle and his private equity backers.This multiple is at the upper end of prevailing sector benchmarks. Nelson Advisors’ January 2026 HealthTech valuation report puts general digital health assets at 4x-6x revenue. But the report notes that premium telehealth and AI‑enabled platforms – those showing strong growth and embedded workflows – command 6x-8x+ revenue multiples.The deal valuation will have caught the attention of other players and investors in Australia’s burgeoning preventative medicine sector, which is already well known for its strong foundation in biotech, innovative digitally-driven health and AI-powered diagnostics.Sector stakeholders will also have noted the wider implications of the Eucalyptus deal, which Nelson Advisors said has turned Hims &amp; Hers into an international “powerhouse” and “represents one of the most significant consolidations in the history of the [global] telehealth industry”.Source: <a href="https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/">https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/</a>

Nelson Advisors featured in Mergermarket: Hims & Hers’ $1.15 Billion Eucalyptus deal signals new era for Australia’s Digital Health

Major themes this week: EU‑level regulatory moves (MDR/IVDR and AI Act alignment), fresh EU digital/health funding instruments, and continued capital flowing into European digital health, with France and Germany especially active.EU regulation and policy The Commission’s 2026 “Health Package” is moving forward with revisions to MDR/IVDR to ease bottlenecks, including more predictable conformity assessments, a codified Helsinki procedure for borderline products, and risk‑based certificate validity rather than fixed terms. Work continues on aligning AI Act “high‑risk” obligations with MDR/IVDR so high‑risk medical AI can follow a single sectoral route instead of duplicated certification, with core AI Act obligations expected to bite around August 2026. EU‑level HTA machinery is now live, with more MedTech expected into joint clinical assessments in 2026, raising the evidentiary bar for pan‑EU digital and AI‑enabled devices. Data protection bodies (EDPB/EDPS) issued a joint opinion on the proposed European Biotech Act this month, signalling closer scrutiny of data‑intensive biotech and digital health models. Public funding and grant landscape Within Horizon Europe 2026–27, a substantial part of a €14bn R&amp;I envelope is earmarked for health and digital technologies, reinforcing medium‑term support for AI, data and platform‑driven health innovation. EIT Health’s 2026 Innovation Validation Call launched, co‑funding up to 50% of late‑stage digital/data/AI health projects (cap €850k) to accelerate clinical validation, regulatory approval, and market launch. Global Health EDCTP3 opened 2026 calls with up to €147m across six topics (TB, LRTIs, HIV, climate‑linked infectious disease), all with clear digital and AI platform angles, plus a joint call offering up to €2.25m per project for digital/AI health research in Sub‑Saharan Africa. Under the Digital Europe Programme, the DIGITAL‑2026‑SKILLS‑09 call closed with 31 proposals received by 3 March, focusing on advanced digital skills, which is relevant for AI and data‑heavy health ecosystems. Private capital and market sentiment In the week of 14–21 March, Europe growth‑stage startups raised about $2.11bn, with notable health‑adjacent raises such as Alan’s €100m round to scale its digital health insurance and services platform. Broader context: February 2026 saw European digital health record roughly $318m across 18 deals, a recalibration from January but interpreted as capital “holding its nerve” rather than exiting the category, with more selectivity around evidence and path to profitability. Analysts note a pivot from early‑stage experiments towards validation‑stage digital health and AI, with capital and public instruments concentrating on companies that are closer to clinical proof and commercial scaling.Ecosystem and NHS‑related signals EU‑level and national fora (e.g., health.tech Basel, Masters of Digital 2026) are increasingly focused on moving from pilots to execution, highlighting AI deployment, prevention systems and digital clinical trials.In the UK, Digital Health Rewired 2026 (this week at the NEC) is spotlighting themes such as integrated care, prevention, and EPR optimisation, framed against a £10bn NHS tech investment programme and ~90% EPR adoption in England. Prior DHSC announcements about 45 NHS remote‑monitoring pilots via the NHS App (targeting ~500k appointments freed per year) remain a reference point for scaling virtual care and self‑reporting tools into mainstream pathways.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;Headline moves in European MedTech this week centre on MDR/IVDR overhaul, EU–Switzerland mutual recognition, and a steady drumbeat of consolidation‑driven dealmaking and infrastructure‑type funding.Regulation: MDR/IVDR “reset” and digitisation The Commission has now formally proposed an MDR/IVDR overhaul aimed at simplifying procedures, easing notified‑body bottlenecks, and reducing shortage risk, with adoption targeted around summer 2026. Key elements include more proportionate clinical evidence requirements for legacy/low‑risk devices, streamlined renewals, and better transition pathways, framed explicitly as pro‑innovation while preserving safety. Parallel legal analysis highlights planned digitisation of compliance: declarations of conformity and certain IFUs in digital form only, mandatory electronic submissions, and digital contact details in EUDAMED (new MDR Art. 110a; IVDR Art. 103a). EU–Switzerland medical devices détente On 2 March, the EU and Switzerland agreed a package updating their Mutual Recognition Agreement, a major political step towards restoring mutual recognition for medical devices after several years of “third‑country” treatment. This is expected to stabilise market access and regulatory cooperation, reducing duplicative conformity assessments and administrative friction for EU and Swiss MedTech exporters. Market structure, risk and M&amp;A tone Sector commentary for 2026 continues to stress “regulation, risk and resilience”: sustained demand and strong fundamentals, but higher compliance costs driving portfolio pruning and reprioritisation of launches. Distressed M&amp;A is framed as a structural feature of 2026 European MedTech, driven by regulatory capital requirements, tighter funding markets and operational pressures forcing under‑scaled assets into sales processes. At the same time, competition for high‑quality, high‑growth assets is expected to intensify, with significant deployable capital targeting category leaders in robotics, neuro, advanced diagnostics and data‑rich devices. Recent capital and infrastructure signals Recent European MedTech briefs spotlight a shift from “shiny innovation” to whether innovation survives contact with operational reality, with themes like AI in hospital operations, clinical‑trial infrastructure, and cyber‑resilience (e.g., hospital AI raises, Stryker cyberattack, JenaValve approval) dominating the week of 16–22 March. Earlier 2026 coverage flagged substantial rounds in cardiology (e.g., ~€83m for FineHeart’s implantable heart‑failure device) and AMR diagnostics (e.g., €24m for ShanX Medtech), underlining investor appetite for high‑acuity hardware‑plus‑data and EU‑priority areas.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors Conferences and Events 2026

Nelson Advisors advised the Clinic Letter AI founders on...

Nelson Advisors served as exclusive advisors to Wellola o...

FemTech startup Daye wins Digital Health Rewired Pitchfes...

Nelson Advisors featured in Mergermarket: Hims & Hers’ $1...

This Week in European MedTech and HealthTech: 27th March ...